The peptides that actually matter, explained

TL;DR

• Semaglutide's cardiovascular outcomes trial ran in over 17,000 adults - 20% fewer major adverse cardiac events, 19% fewer deaths from any cause.
• Tesamorelin is FDA-approved (Egrifta, 2010): pooled phase 3 data in 800+ patients cut visceral fat ~15% versus placebo over 26 weeks - and it returned when treatment stopped.
• Thymosin β4 has real phase 2 human data in venous stasis and pressure ulcers - skin wounds, not tendon - and sits on the WADA prohibited list.
• BPC-157, epitalon, MOTS-c and follistatin 344 rest on animal and mechanistic work - no large randomised human trial for any of them.
• AOD9604 failed a properly powered phase 2b (500+ participants, 24 weeks, halted 2007) and is still sold with the same "stubborn fat" copy.
• FDA Category 2 status governs compounding legality only - the Pharmacy Compounding Advisory Committee reviews BPC-157, TB-500, thymosin α1, CJC-1295, ipamorelin, GHK-Cu, KPV and MOTS-c in July 2026.

Educational content, not medical advice. No doses, protocols or administration details appear anywhere in this guide - those belong with a physician. Regulatory status is stated as of August 2026 and changes; verify before acting.

---

The core problem with peptide content online isn't that it's wrong. It's that everything gets presented at the same confidence level. A compound with two decades of randomised human trials and a mortality benefit sits in the same listicle as a compound tested only in rats - described in the same excited tone, priced the same way, sold from the same site.

So here is the entire landscape organised by evidence tier, with one question asked of every compound: has this been tested in humans, in the population and for the purpose being claimed? By the end you'll be able to place any peptide you encounter on that scale yourself.

The evidence ladder (use this on everything)

The single most useful habit: when you see a claim, ask which tier it's drawn from. Most marketing quietly borrows the tone of tier 1 for compounds sitting at tier 4.

A second question worth asking of any tier is who was studied. Trial populations skewed male for decades, and sex-disaggregated analysis is still inconsistent - so for most of the compounds below, the honest answer about peptides in men and women is not that they behave identically but that nobody adequately checked.

First, the regulatory picture - which is in flux

In September 2023 the FDA placed a long list of peptides into Category 2 of its interim 503A bulk drug substances list - meaning compounding pharmacies could not legally prepare them. Importantly, that wasn't a finding that they're dangerous; it was a finding that the human safety and quality data needed to support compounding hadn't been generated.

As of 2026 that position is being actively revisited: HHS has signalled that a group of these substances - including BPC-157, TB-500, thymosin α1, CJC-1295, ipamorelin, GHK-Cu, KPV and MOTS-c - may return to Category 1, with the Pharmacy Compounding Advisory Committee reviewing them in July 2026. A smaller group, including melanotan II and several growth-hormone-releasing peptides, is expected to remain restricted on safety grounds.

The distinction that gets lost in the headlines: reclassification governs compounding legality only. It does not confer FDA approval, validated indications, standardised dosing, or an established benefit-risk profile. A peptide can be legal to compound and still have no phase 3 evidence behind it. (Detail: the FDA compounding decision.)

Category 1: repair peptides

BPC-157 is a synthetic fragment derived from a protein in gastric juice. The proposed mechanism is genuinely elegant: it appears to upregulate VEGFR2 signalling (driving new blood vessel growth into damaged tissue) and activate the AKT-eNOS pathway (increasing nitric oxide and blood flow to an injury). In tendon studies it accelerated fibroblast migration; it also improves cell survival under oxidative stress.

The honest position: essentially all of that is rats, mice and cell cultures. There is no large randomised controlled trial showing BPC-157 accelerates healing in people. Compelling in rodents and proven in patients are different sentences. Tier 4. (Full guide.)

TB-500 / thymosin β4 works further upstream, increasing how many repair cells the body mobilises and how quickly they migrate and differentiate. Here the human evidence is stronger than most people assume - but concentrated in one place. Phase 2 human trials in venous stasis and pressure ulcers showed measurably faster dermal wound healing versus standard care. That's real peer-reviewed human data.

The evidence thins exactly where the internet gets loudest: tendon, ligament and muscle. Claims about rebuilding a torn rotator cuff are extrapolation from wound-healing and animal data, not trials in that tissue. Tier 3 for skin wounds, tier 4 for musculoskeletal injury.

Two clinical cautions worth stating plainly. Any peptide that promotes cell proliferation deserves real caution in anyone with active or suspected cancer - the mechanism that closes a wound is the mechanism that can help the wrong thing grow. And thymosin β4 and its derivatives are prohibited by the World Anti-Doping Agency, which matters if you compete.

The unglamorous point that outranks all of it: no repair peptide outruns uncontrolled blood glucose, poor sleep or inadequate protein. High blood sugar wrecks the exact machinery - blood flow, collagen synthesis, fibroblast function - these compounds are trying to support. Foundations first isn't a platitude; it's the rate-limiting step.

Category 2: the growth hormone axis

The map first, because it makes the marketing quieter. The pituitary releases growth hormone in pulses, mostly during deep sleep. GH travels to the liver, which converts part of it into IGF-1, and IGF-1 does most of the work at the muscle cell. Every peptide below targets a different point on that chain.

Compound references for the GH-axis peptides Vivre works with: tesamorelin · sermorelin · CJC-1295 (no DAC) · ipamorelin.

Sermorelin deserves a note most guides skip: it was fully FDA-approved in 1990 for diagnosing and treating growth hormone deficiency in children, and was discontinued in 2008 for commercial reasons - manufacturing cost and shrinking demand - not safety or efficacy. That gives it the longest documented human safety history of any GH secretagogue here. It doesn't make it more effective than CJC-1295 milligram for milligram; head-to-head human trials are limited. But if regulatory track record informs how you weigh risk, that's a real difference.

Tesamorelin is the one with directly relevant approved evidence: across pooled phase 3 trials in over 800 patients it reduced visceral fat - the metabolically dangerous fat around the organs - by roughly 15% versus placebo over 26 weeks, with improvements in triglycerides. Its approved indication is HIV-associated lipodystrophy. The critical caveat, which applies to this entire category: when treatment stopped in the trials, the visceral fat came back within months. This is ongoing therapy, not a course you complete. (Full guide.)

Ipamorelin's selling point is selectivity - older compounds in its class also raised cortisol and prolactin, which is self-defeating (cortisol breaks down muscle and promotes fat storage). Combined with CJC-1295, published pharmacodynamic data shows meaningful multiples of increased GH output and IGF-1. The pharmacology is real. What's absent is long-term human safety data - what happens over five or ten years in a healthy adult simply hasn't been studied at the rigour that should precede a casual recommendation.

IGF-1 LR3 carries a specific, underappreciated hazard: IGF-1 shares structural homology with insulin and binds insulin receptors, so it can drop blood glucose significantly. Cases of unexplained recurrent hypoglycaemia traced to undisclosed IGF-1 use are a real clinical picture, not a hypothetical. Anything that behaves like insulin deserves the respect you'd give insulin.

Follistatin 344 neutralises myostatin - the body's governor on muscle mass. The animal data is spectacular (myostatin-null mice with a follistatin transgene reached several times normal muscle mass), and that number drives most of the online enthusiasm. The gap to humans is the widest on this list: the only rigorous human data comes from gene therapy trials in muscular dystrophy - different population, different delivery, different goal. Independent testing of commercially sold follistatin products has repeatedly found contamination and mislabelled concentrations. Tier 4, with quality-control problems on top.

Category 3: aesthetic, immune and longevity

GHK-Cu is a copper-binding tripeptide that occurs naturally in plasma and declines measurably with age - a decline that tracks with slower wound healing and thinner skin. It stimulates fibroblasts to produce collagen, elastin and glycosaminoglycans, and influences a very large number of genes tied to tissue remodelling.

The evidence splits sharply by route. Topical formulations have reasonable published data for modest improvement in fine lines, firmness and pigmentation over months of consistent use. Injectable/systemic use for broader anti-ageing or hair claims has far less rigorous human data - mostly extrapolation from topical and in-vitro work. If someone tells you it reverses ageing systemically, that claim is running ahead of what's published. (Full guide.)

Epitalon proposes to activate telomerase - the enzyme that lengthens the protective caps on chromosomes that shorten with each cell division. In cell culture it increased telomerase expression; in animals it's been associated with modest lifespan extension. Two reasons for caution: the overwhelming majority of the research comes from a single research institution, so independent replication is limited; and there's a legitimate biological tension in chronically activating telomerase, since uncontrolled telomerase activity is associated with cancer cell immortality. That is not evidence epitalon causes cancer - there is none. It means the long-term oncologic safety question hasn't been answered. Tier 4, filed under interesting hypothesis.

Thymosin α1 is a different molecule entirely from thymosin β4 despite the name - this one is about immune regulation and T-cell maturation. It's approved in roughly 35 countries (as Zadaxin) for chronic hepatitis B and certain immunodeficiency states, though never FDA-approved in the US. Meta-analyses of randomised trials in severe sepsis found a significant reduction in 28-day mortality. That is a genuinely high tier of evidence - real mortality data from randomised trials.

But note the population. Essentially all of it comes from severe illness: sepsis, chronic viral hepatitis, cancer patients receiving chemotherapy. There is almost no controlled evidence for use as a general "immune booster" in a healthy adult, which is exactly how it's marketed. A peptide that reduces mortality in septic shock is not automatically a peptide that does anything measurable for a healthy 45-year-old. Tier 3 - right data, wrong context.

MOTS-c is encoded in mitochondrial rather than nuclear DNA, and a single bout of exercise can raise skeletal muscle levels many-fold. Researchers call it an "exercise mimetic" because in animals it produces some of the same metabolic adaptations as training. Human evidence is early and inconsistent, there's no completed human therapeutic trial, and it has a practical problem: poor stability and a short half-life have stalled its development as a drug. Interesting mitochondrial biology; not a proven intervention. (Full guide.)

Category 4: hormonal and quality of life

PT-141 (bremelanotide) is worth including precisely because sexual health gets left out of hormone conversations. It doesn't act on tissue or metabolism - it acts on the brain, activating melanocortin receptors in the hypothalamus, which is a fundamentally different mechanism from erectile dysfunction drugs that work on blood vessels. It's FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder in premenopausal women, and was the first approved for on-demand use. Its approval is narrow - off-label use in other populations, including the men's-health marketing attached to it, has a thinner evidence base than the approval implies. Nausea and a transient blood pressure rise are the notable side effects. Tier 2. (Full guide · vs kisspeptin.)

DSIP (delta sleep-inducing peptide) is the clearest example of research momentum simply stopping. Small human trials in the 1980s produced mixed results - one found modestly fewer awakenings and faster sleep onset, described by the researchers themselves as of limited clinical significance. Since then, essentially nothing: no modern, adequately powered randomised trial, and the mechanism was never fully worked out. Anyone selling DSIP as a proven sleep solution is relying on forty-year-old, small, inconsistent data. If sleep is the goal, the genuinely proven interventions are unglamorous - consistent sleep and wake times, morning light, and limiting alcohol, which fragments deep sleep more than most people realise. (Sleep guide.)

Category 5: the metabolic peptides - where the real evidence lives

This category contains both the weakest and the strongest entries in the whole landscape, which is why it's last.

AOD9604 is the cautionary tale. A fragment of human growth hormone believed to carry its fat-metabolising effects without the growth or glucose effects. Early pilot data looked promising. Then it went through the kind of trial every compound here should face: a properly powered phase 2b study, over 500 participants, 24 weeks, randomised and placebo-controlled. It did not separate from placebo at any dose tested. The programme was halted in 2007 and never advanced. It is still sold today with the same "targets stubborn fat" language it had before the trial existed.

Then the other end of the scale. Semaglutide and tirzepatide are backed by some of the largest, longest, most rigorously controlled trials in obesity medicine - and in semaglutide's case, a cardiovascular outcomes trial in over 17,000 adults showing a 20% reduction in major adverse cardiovascular events and a 19% reduction in death from any cause. That is a documented reduction in the risk of dying. Nothing else in this guide comes close.

Retatrutide (triple agonist) and cagrilintide (amylin analogue) extend the same logic further, with phase 3 data now reading out. Because that whole story deserves its own treatment, it's here: the GLP-1 generations compared.

The bottom line - and where to start

Sort by tier and the landscape resolves quickly. A handful of these compounds are among the best-evidenced drugs in modern medicine. Most sit on animal data and elegant mechanism. One failed outright and is still being sold. The marketing blurs those lines deliberately, because "might work, probably safe, not enough data yet" doesn't sell like "breakthrough."

None of that means the tier-4 compounds are worthless - it means the honest position is unproven, and unproven belongs under supervision, with verified product, in someone whose foundations are already handled. That's the difference between an informed decision and an expensive one.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Semaglutide.

Frequently asked questions

Which peptides actually have human evidence? Semaglutide and tirzepatide have the largest randomised trial evidence, including mortality and cardiovascular outcomes. Tesamorelin, PT-141 and historically sermorelin passed FDA review for narrow indications. Thymosin α1 and thymosin β4 have real trial data but in specific patient populations. BPC-157, epitalon, MOTS-c and follistatin remain animal and mechanistic evidence only.

Does FDA reclassification mean a peptide is approved? No - and this is the most common misreading. Moving between compounding categories governs whether licensed pharmacies may legally prepare a substance. It does not confer FDA approval, validated indications, standardised dosing, or an established benefit-risk profile. A peptide can be legal to compound and still have no phase 3 evidence.

Is BPC-157 proven to heal injuries? Not in humans. The mechanistic and animal data are genuinely compelling, but there is no large randomised controlled trial demonstrating accelerated healing in people. Anyone presenting it as proven is extrapolating from rodent studies.

Related reading

• What are peptides · Peptide side effects · How to choose a peptide clinic · GLP-1 generations compared · Peptides in men and women · Do peptides work? The evidence, and who pays to produce it · Research on what, in whom, measured how
• Part of The Beginner's Guide to Peptides

---

Educational content, not medical advice. This guide deliberately contains no doses, protocols or administration details. Most compounds discussed are not approved for the uses described and several are not approved at all; use should be physician-directed with independently verified product. Regulatory status is stated as of August 2026 and is actively changing. Claims for the Malaysian market are subject to MAB requirements.

References

• FDA, Bulk Drug Substances Used in Compounding Under Section 503A (interim policy categories 1–3); Certain Bulk Drug Substances That May Present Significant Safety Risks (Category 2, September 2023); PCAC review scheduled July 2026. · BPC-157: VEGFR2 and AKT-eNOS signalling, tendon fibroblast outgrowth - preclinical/animal models. · Thymosin β4: phase 2 randomised trials in venous stasis and pressure ulcers; WADA Prohibited List. · Sermorelin (Geref) FDA approval 1990, discontinued 2008 for non-safety reasons (Federal Register, 2013). · Tesamorelin (Egrifta) FDA approval 2010; pooled phase 3 visceral adipose tissue reduction ~15% vs placebo at 26 weeks; regain after discontinuation. · IGF-1/insulin receptor cross-reactivity and hypoglycaemia. · Follistatin/myostatin: preclinical transgenic models; human data limited to gene-therapy trials in muscular dystrophy. · GHK-Cu: Pickart (1973); topical clinical data on fine lines/firmness. · Epitalon: telomerase expression in fibroblast culture; single-institution research base. · Thymosin α1 (Zadaxin): approved in ~35 countries, not FDA-approved; meta-analyses of RCTs in severe sepsis showing reduced 28-day mortality. · MOTS-c: mitochondrial-derived peptide, exercise-induced expression, stability/half-life limitations. · Bremelanotide (Vyleesi) FDA approval 2019, RECONNECT phase 3. · DSIP: small 1980s trials, inconsistent results. · AOD9604: phase 2b (n>500, 24 weeks) failed to separate from placebo; programme discontinued 2007. · Semaglutide: STEP programme; SELECT (n>17,000) 20% MACE reduction, 19% all-cause mortality reduction.